Pharmakon Advisors LP

Search
⚲

Total AUM ($B) Copy

Type	Form D Funds	Date	Sold	AUM
PE	Biopharma Credit Investments V Master LP	[2020-03-27]	1,382.8 M	1,870.1 M
	Filed 2025-05-28 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $50,000 · Revenue Decline to Disclose
PE	Pharmakon Opportunities LP	2019-03-29		46.5 M
PE	Biopharma Secured Investments III Cayman Feeder LP	2018-03-29		5.4 M
PE	Biopharma Secured Investments III Holdings Cayman LP	2018-03-29		16.7 M
PE	Biopharma Secured Investments III Partners LP	2018-03-29		11.8 M
PE	Biopharma Credit Investments IV SARL	[2016-03-29]
	Filed 2015-12-08 (D) · Exemption 506(b) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose
PE	Biopharma Secured Investments III SARL	[2014-03-31]	247.8 M	344.9 M
	Offered $247,750,000 · Filed 2013-07-17 (D) · Exemption 506 · Minimum $100,000 · Duration One year or less · Net Assets Decline to Disclose
PE	Biopharma Secured Debt Fund LP	[2012-02-15]	155.5 M	121.3 M
	Filed 2012-02-15 (D) · Exemption 506, 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Finder's Fee $19,135 · Revenue Decline to Disclose
PE	Biopharma Secured Investments II SARL	[2012-02-15]	184.1 M	138.5 M
	Filed 2011-03-18 (D) · Exemption 506 · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose

AUM Breakdown	Accounts	AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals)	0	0.0
(b) Individuals (high net worth individuals)	0	0.0
(c) Banking or thrift institutions	0	0.0
(d) Investment companies	0	0.0
(e) Business development companies	0	0.0
(f) Pooled investment vehicles	4	1.9
(g) Pension and profit sharing plans	0	0.0
(h) Charitable organizations	0	0.0
(i) State or municipal government entities	0	0.0
(j) Other investment advisers	0	0.0
(k) Insurance companies	0	0.0
(l) Sovereign wealth funds and foreign official institutions	0	0.0
(m) Corporations or other businesses not listed above	0	0.0
(n) Other	1	1.2
Total	5	3.0
By Discretionary
Discretionary	5	3.0
Non-Discretionary	0	0.0
Total	5	3.0
By Non-United States Persons
Non-United States Persons		1.6
United States Persons		1.4
Total	5	3.0

Form D Directors	Role	# Filings	# Firms
Martin Galliver	Director	4	4
Hugo Froment	Executive Officer	7	3
Benjamin Schliemann	Executive Officer	5	3
David Catala	Executive Officer	5	2
Pedro Gonzalez de Cosio	Executive Officer	5	2
Biopharma Credit Investments V GP LLC	Director	3	2
Pablo Legoretta	Executive Officer	2	2
Pierre Claudel	Executive Officer	2	2
Andrew O'shea	Executive Officer	2	2
Miroslava Jassova	Director	1	1
Myla Tolentino	Director	1	1
Fanny Auenallah	Executive Officer	1	1

Comparable Firms	State	AUM
Ampersand Management LLC ✚	MA	3,093.5 M
Calera Capital Advisors LP ✚	CA	3,089.8 M
Emerald Lake Capital Management LP ✚	CA	3,064.9 M
Gamut Capital Management LP ✚	NY	3,049.2 M
ClariVest Asset Management LLC ✚	CA	3,048.4 M
Anthos Management LP ✚	CA	3,043.7 M
Overland Advisors LLC ✚	NY	3,034.4 M
Argonaut Private Capital LP ✚	OK	3,008.0 M
Trinity Hunt Management LP ✚	TX	2,994.5 M
Pacific Avenue Capital Partners Management Company LLC ✚	CA	2,978.2 M

Assets, Funds, Holdings